03/1

UTILITY PATENT PLICATION TRANSMITTAL (Larg Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. D-2947CIP

Total Pages in this Submission

TO THE ASSISTANT COMMISSIONER FOR PATENTS

B x Patent Application Washington, D.C. 20231

a d		Washin	gton, D.C. 20231		
		35 U.S.C. 111(a) a	and 37 C.F.R. 1.53	(b) is a new utility patent ap	plication for an
COMPOSIT		DS FOR TREAT	ING GONADOTR	ROPHIN RELATED ILLNI	ESSES
					11033 U.S. PTO
and invented by	r				
Stephen Dor					
				Jun	nbo
If a CONTINU	ATION APPLICATION	I, check appropria	ate box and supply	the requisite information:	
🖆 🗆 Continua	tion 🗌 Divisional	□ Continua	tion-in-part (CIP)	of prior application No.:	09/692,811
Which is a:					
☐ Continua ■Which is a:	tion Divisional	☐ Continua	tion-in-part (CIP)	of prior application No.:	
Continua	tion Divisional	☐ Continua	tion-in-part (CIP)	of prior application No.:	
Enclosed are:		Applic	ation Elements		
1. ⊠ Fili	ng fee as calculated a	nd transmitted as	described below		
	ng lee as calculated a	na iransmittea as	described below		
° 2. ⊠ Spo	ecification having	61	pages and in	ncluding the following:	
a. 🛚	Descriptive Title of t	ne Invention			
b. 🛛	Cross References to	Related Applicat	ions (if applicable)		
с. 🗀	Statement Regardin	g Federally-spons	sored Research/De	velopment (if applicable)	
d. 🗆	Reference to Microfi	che Appendix (if a	applicable)		
e. 🛚	Background of the li	nvention			
f. 🛚	Brief Summary of th	e Invention			
g. 🛭	Brief Description of	the Drawings <i>(if di</i>	rawings filed)		
h. ⊠	Detailed Description	•	- ,		
i. 🛚	Claim(s) as Classifie				
 j. ⊠	Abstract of the Disc				

UTILITY PATENT PLICATION TRANSMITTAL (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. D-2947CIP

Total Pages in this Submission

	Applicati n Elements (C ntinued)														
3	×	Drawing(s) (when necessary as prescribed by 35 USC 113)													
	a.		Formal	١	Number of She	ets									
	b.	×	Informal	١	Number of She	ets		···							
4.	X	Oath	n or Declaratio	on											
	a.	×	Newly execu	ted (orig	inal or copy)		Une	exe	cuted						
	b.	Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional application only)													
	C.	☑ With Power of Attorney ☐ Without Power of Attorney													
	d.	DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. 1.63(d)(2) and 1.33(b).													
5.		Incorporation By Reference (usable if Box 4b is checked) The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.													
6.		Computer Program in Microfiche (Appendix)													
7.	×	Nucleotide and/or Amino Acid Sequence Submission (if applicable, all must be included)													
	a.	☑ Paper Copy													
	b.	□ Computer Readable Copy (identical to computer copy)													
	C.	Statement Verifying Identical Paper and Computer Readable Copy													
					Accompar	ying A	pplic	catio	on Pa	rts					
8.	×	Assi	ignment Pape	rs (cove	r sheet & docu	ment(s))									
9.		37 CFR 3.73(B) Statement (when there is an assignee)													
10.		English Translation Document (if applicable)													
11.	×	Information Disclosure Statement/PTO-1449 Copies of IDS Citations													
12.		Preliminary Amendment													
13.	×	Acknowledgment postcard													
14.	×	Certificate of Mailing													
			First Class	⊠ Ex	press Mail (Sp	ecify La	bel N	No.)	: <u>EL</u>	608287	218	BUS	 		

UTILITY PATENT PLICATION TRANSMITTAL (Larg Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. D-2947CIP

Total Pages in this Submission

		Acc mpanying Applicati n Parts (Continued)
15.		Certified Copy of Priority Document(s) (if foreign priority is claimed)
16.	×	Additional Enclosures (please identify below):
		application data sheet
		Request That Application Not Be Published Pursuant To 35 U.S.C. 122(b)(2)
17.		Pursuant to 35 U.S.C. 122(b)(2), Applicant hereby requests that this patent application not be published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in this application has not and will not be the subject of an application filed in another country, or under a multilateral international agreement, that requires publication of applications 18 months after filing of the application.
		Warning
		An applicant who makes a request not to publish, but who subsequently files in a foreign country or under a multilateral international agreement specified in 35 U.S.C. 122(b)(2)(B)(i), must notify the Director of such filing not later than 45 days after the date of the filing of such foreign or international application. A failure of the applicant to provide such notice within the prescribed period shall result in the application being regarded as abandoned, unless it is shown to the satisfaction of the Director that the delay in submitting the notice was unintentional.

UTILITY PATENT PLICATION TRANSMITTAL (Larg Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. D-2947CIP

Total Pages in this Submission

Fee Calculation and Transmittal

CLAIMS AS FILED									
For	#Filed	#Allowed	#Extra		Rate		Fee		
Total Claims	25	- 20 =	5	×	\$18.00		\$90.00		
Indep. Claims	4	- 3 =	1	×	\$80.00		\$80.00		
Multiple Dependent Claims (check if applicable)							\$0.00		
						BASIC FEE	\$710.00		
OTHER FEE (spec	cify purpose)		assignment	recordati	ion		\$40.00		
					TOTAL	FILING FEE	\$920.00		
						1)			

	A check in the amou	nt of	to	cover the filing	g fee is enclosed.	
X	The Commissioner is	hereby authoriz	ed to char	ge and credit D	eposit Account No.	01-0885
,	as described below.	A duplicate copy	of this she	eet is enclosed	•	
	Charge the a	amount of \$9	920.00	as filing fee.		
	Credit any or	verpayment.				
	Charge any	additional filing fe	es require	d under 37 C.F	R. 1.16 and 1.17.	
	☐ Charge the i	ssue fee set in 3	7 C.F.R. 1.	18 at the mailir	ng of the Notice of Allo	wance,
		37 C.F.R. 1.311(t			Many	Uhr-
						Signature
				F	rank J. Uxa	

Stout, Uxa, Buyan & Mullins LLP

4 Venture, Suite 300 Irvine, California 92618 Tel: 949-450-1750

CC:

Dated: March 15, 2001

Docket: D-2947CIP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application:
Stephen Donovan
/ BOX NEW APP FEE
/
Filed: Herewith
/
For: COMPOSITIONS AND METHODS FOR
TREATING GONADOTROPHIN RELATED /

ILLNESSES

EXPRESS MAIL MAILING LABEL NO.

ELP0958357902

Date of Deposit: March 15, 2001

I hereby certify that the following documents as identified below are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under CFR 1.10 on the date indicated above and are addressed to the Commissioner for Patents, Box New App Fee, Washington, D.C. 20231:

- 1. Specification/Claims/Abstract 61 pages
- 2. <u>1</u> sheet of informal drawings;
- 3. Transmittal letter;
- 4. Application Data Sheet;
- 5. Declaration and Power of Attorney;
- 6. Assignment and Recordation Cover Sheet;
- 7. Sequence listing in paper and CRF and statement verifying identical computer readable and paper copy;
- 8. Information Disclosure Statement:
- 9. PTO-1449 and copies of cited references including co-pending applications;
- 10. Return Receipt postcard.

Each of the 10 above-identified documents are enclosed herewith.

Respectfully submitted,

Jean F. Heuler, Office of

Deuler

Frank J. Uxa

Attorney for Applicant Registration No. 25,612 4 Venture, Suite 300 Irvine, CA 92618

Telephone 949/ 450-1750 Facsimile 949/ 450-1764

that the first and that that that that the set that well and and